Nissim Mashiach Net Worth

Nissim Mashiach biography

Nissim Mashiach serves as Independent Director of the Company. He has served as a member of our Board since January 2017. Today he serves as a co-founder of Nubiyota LLC, a microbiome focused, clinical stage company. He served as the President and Chief Executive Officer of Macrocure, Ltd. from June 2012 until its merger with Leap in January 2017. He is also currently a member of the board of directors at Mediwound Ltd. He also previously served as General Manager at Ethicon, a Johnson & Johnson company, from January 2009 to January 2012. Prior to then, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals, Inc., a public company acquired by Johnson & Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership positions at several pharmaceutical companies. He has been a board and audit committee member of Mediwound Ltd. (Nasdaq: MDWD) since June 2017. He holds an MBA from the University of Manchester, England, an MPharmSc from the Hebrew University, Jerusalem, Israel, and a BSc, Chemical Engineering from the Technion-Israel Institute of Technology, Haifa, Israel.

How old is Nissim Mashiach?

Nissim Mashiach is 59, he's been the Independent Director of Leap Therapeutics Inc since 2017. There are 5 older and 5 younger executives at Leap Therapeutics Inc. The oldest executive at Leap Therapeutics Inc is James Cavanaugh, 82, who is the Independent Director.

What's Nissim Mashiach's mailing address?

Nissim's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.

Insiders trading at Leap Therapeutics Inc

Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli oraz Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.

What does Leap Therapeutics Inc do?

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.

Leap Therapeutics Inc executives and stock owners

Leap Therapeutics Inc executives and other stock owners filed with the SEC include:

• Douglas Onsi,
  President, Chief Executive Officer, Director
• Augustine Lawlor,
  Chief Operating Officer
• Christopher Mirabelli,
  Chairman of the Board
• Cynthia Sirard,
  Chief Medical Officer
• Mark O'Mahony,
  Chief Manufacturing Officer
• Nissim Mashiach,
  Independent Director
• Joseph Loscalzo,
  Independent Director
• William Li,
  Independent Director
• Thomas Dietz,
  Lead Independent Director
• James Cavanaugh,
  Independent Director
• Monica Bertagnolli,
  Independent Director
• John W Littlechild,
  Director
• Ventures Ix, L.P.Healthcare...,
  
• Harold R Werner,
  10% owner
• Lilly & Co Eli,
  10% owner
• Patricia A. Martin,
  Director
• Christian M Richard,
  Director
• Richard Schilsky,
  Director
• Advisors Llcperceptive Life...,
  
• Ventures Viii, L.P.Health C...,
  
• Jason Baum,
  Chief Scientific Officer
• Christine Granfield,
  VP, Head of Reg Affairs/Qual
• Ltd. Bei Gene,,
  10% owner